ReviewCurrent neurology and neuroscience reports2013
Meningioma.
Review in Current neurology and neuroscience reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pooled it
- Efficacy of radiotherapy and stereotactic radiosurgery as adjuvant or salvage treatment in atypical and anaplastic (WHO grade II and III) meningiomas: a systematic review and meta-analysis.Neurosurgical review · 2023Pooled it
- A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma.Journal of neuro-oncology · 2023Pooled it
- Postoperative Adjuvant Radiotherapy in Atypical Meningioma Patients: A Meta-Analysis Study.Frontiers in oncology · 2021Pooled it
- Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.Cancer biology & therapy · 2020Pooled it
- A Novel Descriptive Framework for Petroclival and Temporal Bone Meningioma Surgical Outcomes.The Laryngoscope · 2026Article
- MRI-based brain tumor detection through an explainable EfficientNetV2 and MLP-mixer attention architecture.Physical and engineering sciences in medicine · 2026Article
- Altitudinal Visual Field Defect as the Presenting Sign of a Brain Tumor: A Case Report.Clinical case reports · 2026Article
- Survival Outcomes and Prognostic Factors in Patients with Meningioma: A Single-Center Study at the Indonesian National Cancer Center Dharmais Hospital (2019-2025).Current oncology (Toronto, Ont.) · 2026Article
- Emerging trends in cell-based therapies: contemporary advances and ethical considerations in translational neurosurgical oncology.Journal of neuro-oncology · 2025Review
- NMR-Based Metabolomic Profiling for Brain Cancer Diagnosis and Treatment Guidance.Metabolites · 2025Review
- Review
- Advancements in the application of MRI radiomics in meningioma.Radiation oncology (London, England) · 2025Review
- Precision radiotherapy with molecular-profiling of CNS tumours.Journal of neuro-oncology · 2025Review
- A retrospective observational study of risk factors for postoperative meningitis following resection of meningioma.The Journal of international medical research · 2025Observational
- Impact of patient ethnicity, socioeconomic deprivation, and comorbidities on length of stay after cranial meningioma resections: A public healthcare perspective.Surgical neurology international · 2025Article
- Article
- Article
- Relationship between the Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Brain Tumors.International journal of molecular sciences · 2024Article
- Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas represent the most common primary brain tumor and comprise 3 World Health Organization (WHO) grades, the most frequent being WHO grade I (90%). Surgery is mandatory to establish the diagnosis and to remove the tumor; however, complete resection can be achieved in only <50% of patients. Depending on the extent of resection, tumor location and the WHO grade radiation therapy can be applied. The issue of systemic treatment such as chemotherapy or targeted therapy (eg, somatostatin receptors, antiangiogenic agents) is yet not solved, particularly as current data are derived from small uncontrolled series in patients with long-standing disease and after several pretreatments. A more thorough understanding of molecular genetics, signaling pathways and prognostic factors in meningiomas should lead to the design of studies which stratify according to these factors. These studies have to be conducted in newly diagnosed patients after incomplete resection and in tumors of WHO grade II and III.
Indexed as
Identifiers
23463172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.